[Skip to Content]

wet AMD

New Eye Journal Collection: Avastin and Wet AMD

Eye, the journal of The Royal College of Ophthalmologists, has this week published their online collection drawing together papers published on Avastin and Wet AMD in 2018. Members will no doubt be aware of the issue, and ongoing work by the College in campaigning since 2012 for the use of Avastin in treatment for wet

Use of Avastin (bevacizumab) in age related macular degeneration

Updated Statement from The Royal College of Ophthalmologists In 2011 a working group of The Royal College of Ophthalmologists released a statement regarding the use of Avastin (bevacizumab) in medical ophthalmology. It found that Avastin and Lucentis (ranibizumab) were equally effective in the treatment of neovascular age-related macular degeneration (AMD) and that there was no

Choice of anti VEGF agents for wet AMD treatments

College Statement Ophthalmologists have a choice of two anti-VEGF agents for the treatment of wet AMD, following NICE guidance on Ranibizumab (TA155) and Aflibercept (TA294). Photodynamic therapy is also licensed and approved and still has a role in a small subset of patients.  An anti-VEGF agent is generally used for the treatment of wet AMD

Survey results show under resourced eye clinics put patients’ sight at risk

Press Release UK survey by the Macular Society and the Royal College of Ophthalmologists highlights concerns over eye clinic capacity Thousands of elderly people with eye disease are receiving poor or very poor NHS services according to a survey of hospital ophthalmologists. The survey, by the Macular Society and the Royal College of Ophthalmologists, asked